Jung-Woo Choi1, Younghye Kim, Ju-Han Lee, Young-Sik Kim. 1. Department of Pathology, Korea University Ansan Hospital, 516, Gojan-1 Dong, Danwon-Gu, Ansan-Si, Gyeonggi-Do, 425-707, Republic of Korea.
Abstract
PURPOSE: Our study aims to investigate the expressions of β-tubulin isotypes and their significances in urothelial carcinoma of the bladder (UCB) as altered expression of a specific β-tubulin isotype is associated with chemoresistance and poor prognosis in other malignancies. MATERIALS AND METHODS: Expression of β-tubulin isotypes was retrospectively examined in 342 UCB samples obtained from 1995 to 2010 by immunohistochemistry. RESULTS: TUBB1 (307/342, 89.8 %) was most frequently overexpressed in the cytoplasm of UCB cases, followed by TUBB4 (101/342, 29.5 %), TUBB2 (85/342, 24.9 %), and TUBB3 (60/342, 17.5 %). TUBB1 overexpression was associated with older age (p = 0.032), high WHO grade (p = 0.001), and advanced TNM stage (p = 0.006). High levels of TUBB2 expression were associated with high WHO grade (p < 0.001), advanced TNM stage (p < 0.001), and non-papillary growth pattern (p = 0.007). TUBB3 overexpression was related to high WHO grade (p = 0.029). In univariate and multivariate survival analyses, TUBB1 overexpression was associated with poor recurrence-free survival (RFS) rates of all cases (hazard ratio 1.98, p = 0.031) and of the patients with transurethral and/or partial resection (hazard ratio 2.12, p = 0.031). TUBB2 overexpression was correlated with a short RFS of the patients with T2-T4 stages (hazard ratio 3.48, p = 0.007). TUBB3 overexpression was related to a poor RFS of the patients undergoing radical cystectomy (hazard ratio 5.90, p = 0.002). CONCLUSIONS: High TUBB1, TUBB2, and TUBB3 expressions are associated with unfavorable clinicopathologic factors and are independent prognostic factors for recurrence-free survival of UCB.
PURPOSE: Our study aims to investigate the expressions of β-tubulin isotypes and their significances in urothelial carcinoma of the bladder (UCB) as altered expression of a specific β-tubulin isotype is associated with chemoresistance and poor prognosis in other malignancies. MATERIALS AND METHODS: Expression of β-tubulin isotypes was retrospectively examined in 342 UCB samples obtained from 1995 to 2010 by immunohistochemistry. RESULTS:TUBB1 (307/342, 89.8 %) was most frequently overexpressed in the cytoplasm of UCB cases, followed by TUBB4 (101/342, 29.5 %), TUBB2 (85/342, 24.9 %), and TUBB3 (60/342, 17.5 %). TUBB1 overexpression was associated with older age (p = 0.032), high WHO grade (p = 0.001), and advanced TNM stage (p = 0.006). High levels of TUBB2 expression were associated with high WHO grade (p < 0.001), advanced TNM stage (p < 0.001), and non-papillary growth pattern (p = 0.007). TUBB3 overexpression was related to high WHO grade (p = 0.029). In univariate and multivariate survival analyses, TUBB1 overexpression was associated with poor recurrence-free survival (RFS) rates of all cases (hazard ratio 1.98, p = 0.031) and of the patients with transurethral and/or partial resection (hazard ratio 2.12, p = 0.031). TUBB2 overexpression was correlated with a short RFS of the patients with T2-T4 stages (hazard ratio 3.48, p = 0.007). TUBB3 overexpression was related to a poor RFS of the patients undergoing radical cystectomy (hazard ratio 5.90, p = 0.002). CONCLUSIONS: High TUBB1, TUBB2, and TUBB3 expressions are associated with unfavorable clinicopathologic factors and are independent prognostic factors for recurrence-free survival of UCB.
Authors: George Pentheroudakis; Anna Batistatou; Konstantine T Kalogeras; Ralf Kronenwett; Ralph M Wirtz; Evangelos Bournakis; Anastasia G Eleftheraki; Dimitrios Pectasides; Mattheos Bobos; Irini Papaspirou; Sevasti Kamina; Helen Gogas; Angelos K Koutras; Nicholas Pavlidis; George Fountzilas Journal: Breast Cancer Res Treat Date: 2011-03-09 Impact factor: 4.872
Authors: Eva-Maria Schnaeker; Rainer Ossig; Thomas Ludwig; Rita Dreier; Hans Oberleithner; M Wilhelmi; Stefan W Schneider Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Kevin J Cullen; Lisa Schumaker; Nikolaos Nikitakis; Olga Goloubeva; Ming Tan; Nicholas J Sarlis; Robert I Haddad; Marshall R Posner Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: E Du; Chao Lu; Fei Sheng; Changying Li; Hong Li; Na Ding; Yue Chen; Ting Zhang; Kuo Yang; Yong Xu Journal: Cancer Manag Res Date: 2018-08-29 Impact factor: 3.989